4.7 Review

Tolerability and SCFA production after resistant starch supplementation in humans: a systematic review of randomized controlled studies

期刊

AMERICAN JOURNAL OF CLINICAL NUTRITION
卷 115, 期 3, 页码 608-618

出版社

ELSEVIER SCIENCE INC
DOI: 10.1093/ajcn/nqab402

关键词

resistant starch; tolerability; short-chain fatty acid; systematic review; randomized studies

资金

  1. Government of Canada through Genome Canada
  2. Ontario Genomics Institute [OGI-149]
  3. Ontario Ministry of Economic Development and Innovation [13440]
  4. W. Garfield Weston Foundation
  5. University of Ottawa Faculty of Medicine Distinguished Clinical Research Chair in Pediatric Inflammatory Bowel Disease Award
  6. Ottawa Hospital Anesthesia Alternate Funds Association
  7. University of Ottawa Junior Clinical Research Chair in Innovative Translational Research

向作者/读者索取更多资源

The study reviewed 39 randomized trials on the effects of resistant starch (RS) supplementation in adults, finding that RS supplementation was well tolerated and most studies showed an increase in short-chain fatty acid (SCFA) production.
Background: Resistant starches (RSs) have been advocated as a dietary supplement to address microbiota dysbiosis. They are postulated to act through the production of SCFAs. Their clinical tolerability and effect on SCFA production has not been systematically evaluated. Objectives: We conducted a systematic review of RS supplementation as an intervention in adults (healthy individuals and persons with medical conditions) participating in randomized controlled trials. The primary outcome was tolerability of RS supplementation, the secondary outcome was SCFA production. Methods: MEDLINE, Embase, and the Cochrane Central Register were searched. Articles were screened, and data extracted, independently and in duplicate. Results: A total of 39 trials met eligibility criteria, including a total of 2263 patients. Twenty-seven (69%) studies evaluated the impact of RS supplementation in healthy subjects whereas 12 (31%) studies included individuals with an underlying medical condition (e.g.. obesity, prediabetes). Type 2 RS was most frequently investigated (29 studies). Of 12 studies performed in subjects with health conditions, 11 reported on tolerability. All studies showed that RS supplementation was tolerated; 9 of these studies used type 2 RS with doses of 20-40 g/d for >4 wk. Of 27 studies performed in healthy subjects, 20 reported on tolerability. In 14 studies, RS supplementation was tolerated, and the majority used type 2 RS with a dose between 20 and 40 g/d. Twenty-one (78%) studies reporting SCFAs used type 2 RS with a dose of 20-40 g/d for 14 wk. In 16 of 23 studies (70%), SCFA production was increased, in 7 studies there was no change in SCFA concentration before and after RS supplementation, and in 1 study SCFA concentration decreased. Conclusions: Available evidence suggests that RS supplementation is tolerated in both healthy subjects and in those with an underlying medical condition. In addition, SCFA production was increased in most of the studies.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据